Skip to Main Content

Paper Details

Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
Eur Urol
49
2020
Author NameAffiliation
Pedro Isaacsson VelhoJohns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins University
Michael A CarducciJohns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins University, USA Brady Urological Institute
Channing J PallerJohns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins University
Mark C MarkowskiJohns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins University
Mario A EisenbergerJohns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins University, USA Brady Urological Institute
Emmanuel S AntonarakisJohns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins University, USA Brady Urological Institute
  • 1 - 6

Datasets